Brief: Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes

Clearside Biomedical,

09/10/2024 12:05

Clearside Biomedical Inc  CLSD.O :
    * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
ODYSSEY PHASE 2B TRIAL OF SUPRACHOROIDAL CLS-AX IN WET AMD
ACHIEVING ALL PRIMARY AND SECONDARY OUTCOMES
    * CLEARSIDE BIOMEDICAL INC - ODYSSEY PHASE 2B TRIAL ACHIEVES
PRIMARY AND SECONDARY OUTCOMES
    * CLEARSIDE BIOMEDICAL INC - CLS-AX SHOWS WELL-TOLERATED
SAFETY
PROFILE THROUGH WEEK 36
    * CLEARSIDE BIOMEDICAL INC - CLS-AX REDUCED TREATMENT BURDEN
BY
84% OVER 6 MONTHS

Source text for Eikon:  ID:nGNXbwW5Q2 
Further company coverage:  CLSD.O